Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Change in Cash (2019 - 2025)

Historic Change in Cash for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to -$37.3 million.

  • Strata Critical Medical's Change in Cash fell 43594.83% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10954.47%. This contributed to the annual value of -$9.4 million for FY2024, which is 3913.78% up from last year.
  • According to the latest figures from Q3 2025, Strata Critical Medical's Change in Cash is -$37.3 million, which was down 43594.83% from $24.6 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Change in Cash ranged from a high of $185.0 million in Q2 2022 and a low of -$37.3 million during Q3 2025
  • Its 5-year average for Change in Cash is $9.3 million, with a median of -$2.1 million in 2021.
  • The largest annual percentage gain for Strata Critical Medical's Change in Cash in the last 5 years was 714404.26% (2021), contrasted with its biggest fall of 103580.15% (2021).
  • Strata Critical Medical's Change in Cash (Quarter) stood at -$4.4 million in 2021, then tumbled by 96.49% to -$8.6 million in 2022, then fell by 8.08% to -$9.3 million in 2023, then skyrocketed by 80.99% to -$1.8 million in 2024, then tumbled by 2020.64% to -$37.3 million in 2025.
  • Its Change in Cash was -$37.3 million in Q3 2025, compared to $24.6 million in Q2 2025 and $16.0 million in Q1 2025.